| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 02/17/2005 | US20050037006 Antithrombotic agents |
| 02/17/2005 | US20050037005 5c8 Antigen |
| 02/17/2005 | US20050037004 An aglycosylated antibody having a binding affinity for the CD3 antigen complex; antiinflammatory, antiarthritic agents |
| 02/17/2005 | US20050037003 Administering a soluble lymphotoxin- beta receptor, an antibody directed against LT- beta receptor, or an antibody directed against surface LT ligand with a carrier; multiple sclerosis, vision defects, psoriasis, inflammatory bowel disease; antidiabetic agents |
| 02/17/2005 | US20050037002 Synergistic mixture of a blocking agent of an inhibitory receptor or stimulant of an activating receptor of natural killer cells and an antibody that can be bound by the CD16 antigen; efficiency is enhanced through the increase of the antibody-dependent cellular cytoxicity mechanism |
| 02/17/2005 | US20050037001 APC targeting conjugate, an antigen-presenting cell contacted with such conjugate, their medical use, and methods of production |
| 02/17/2005 | US20050037000 A breast, ovarian, prostate, cervical, or pancreatic carcinoma antigen with at least one amino acid modification relative to a wild-type Fc region and that binds Fc gamma RIIA with a greater affinity; anticarcinogenic, antiinflammatory and antiarthritic agents |
| 02/17/2005 | US20050036995 Immunogens; tumor antigens; kits |
| 02/17/2005 | US20050036991 For preventing and/or treating transplant/xenotransplant rejection; interleukin-1B converting enzyme inhibitors |
| 02/17/2005 | US20050036942 killing a prostate stem cell antigen (PSCA) expressing cancer cell, comprising contacting the cancer cell with an isolated PSCA antibody that internalizes upon binding to PSCA on a mammalian cell in vivo; prostate cancer, bladder cancer and lung cancer |
| 02/17/2005 | CA2555323A1 Polypeptide specific to liver cancer, polynucleotide coding for the polypeptide, and rna molecule suppressing expression of the polypeptide |
| 02/17/2005 | CA2537555A1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 02/17/2005 | CA2535517A1 Product comprising a c4bp core protein and a monomeric antigen, and its use |
| 02/17/2005 | CA2534973A1 Anti-fcrn antibodies for treatment of auto/allo immune conditions |
| 02/17/2005 | CA2534899A1 Polypeptides having brain-localizing activity and uses thereof |
| 02/17/2005 | CA2534898A1 Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| 02/17/2005 | CA2534661A1 Osteoarthritis biomarkers and uses thereof |
| 02/17/2005 | CA2534659A1 A variant cell surface molecule associated with cancer |
| 02/17/2005 | CA2534658A1 Trefoil factor 3 (tff3) as a target for anti-cancer therapy |
| 02/17/2005 | CA2532759A1 Active or passive immunization against proapoptotic neurotrophins for the treatment and/or prevention of neurodegenerative diseases |
| 02/17/2005 | CA2532312A1 Process for the production of fine chemicals in plants |
| 02/17/2005 | CA2531501A1 Reagents, methods and kits for detecting feed enzymes |
| 02/17/2005 | CA2530482A1 Self-assembling peptides incorporating modifications and methods of use thereof |
| 02/17/2005 | CA2529623A1 Antibodies specific for sclerostin and methods for increasing bone mineralization |
| 02/17/2005 | CA2526274A1 Prostate stem cell antigen (psca) variants and subsequences thereof |
| 02/16/2005 | EP1507007A1 Cell cycle related proteins |
| 02/16/2005 | EP1506787A1 Vascular endothelial cell growth factor antagonists |
| 02/16/2005 | EP1506408A2 Methods for diagnosing htlv-i-mediated diseases |
| 02/16/2005 | EP1506406A2 Diagnosis of hepatocellular carcinoma |
| 02/16/2005 | EP1506317A2 Marker molecules associated with lung tumors |
| 02/16/2005 | EP1506312A2 Metalloprotease peptide substrates and methods |
| 02/16/2005 | EP1506306A2 Nucleic acids encoding a g-protein coupled receptor involved in islet cell signaling |
| 02/16/2005 | EP1506295A2 Muteins of placental growth factor type 1, preparation method and application thereof |
| 02/16/2005 | EP1506291A2 Novel phospholipases and uses thereof |
| 02/16/2005 | EP1506286A2 Neutralizing human anti-igfr antibody |
| 02/16/2005 | EP1506285A2 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| 02/16/2005 | EP1506237A1 Treatment of cancer by the use of anti fas antibody |
| 02/16/2005 | EP1506236A2 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same |
| 02/16/2005 | EP1506235A1 Method for producing monoclonal antibodies |
| 02/16/2005 | EP1506224A1 Polypeptide antigen inducing hiv neutralizing antibodies |
| 02/16/2005 | EP1506215A2 Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same |
| 02/16/2005 | EP1506018A1 Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s) |
| 02/16/2005 | EP1506013A1 Chimeric allograft tolerance induction, monitoring and maintenance |
| 02/16/2005 | EP1506012A1 Use of a vaccine for active immunization against cancer |
| 02/16/2005 | EP1506011A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 02/16/2005 | EP1506009A2 Glucan-based vaccines |
| 02/16/2005 | EP1506002A2 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies |
| 02/16/2005 | EP1505873A2 Universal chimera bank |
| 02/16/2005 | EP0634896B1 Evaluation of patients with progressive immunosuppression |
| 02/16/2005 | CN1582301A Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 02/16/2005 | CN1582165A Antibodies to CD40 |
| 02/16/2005 | CN1582164A Antigen arrays for treatment of bone disease |
| 02/16/2005 | CN1580247A Esophagus carcinoma monoclonal antibody, and its radioactive marker and chemical cross-linked substance, and its use |
| 02/16/2005 | CN1580072A SARS coronary virus nail protein high-immune-protosegment, coding sequence and its use |
| 02/16/2005 | CN1189564C Modulators of the function of receptors of the TNF/NGF receptor family |
| 02/16/2005 | CN1189484C Recombined human CD11a monclone antibody and its preparation and medicinal composition |
| 02/16/2005 | CN1189483C Humanized CD3-resisting monoclonal antibody |
| 02/16/2005 | CN1189213C Tolerance to xenograft |
| 02/15/2005 | US6855871 Transgenic plant for use in generation and maintenance of preferential storage proteins in seeds |
| 02/15/2005 | US6855828 Administering to a mammal a fluorine-18 containing 2-nitro-n-(carboxamidomethyl)imidazole derivatives and imaging |
| 02/15/2005 | US6855810 Ligands directed to the non-secretory component, non-stalk region of plgR and methods of use thereof |
| 02/15/2005 | US6855808 Prevent cell differentiation; culture product; genetic engineered protein |
| 02/15/2005 | US6855806 Comprises secreted polypeptide for diagnosis and treatment of tumors, nervous system, reproductive and muscular disorder |
| 02/15/2005 | US6855804 Covalently reactive transition state analogs and methods of use thereof |
| 02/15/2005 | US6855803 Protein having hemolytic activity and gene encoding the protein |
| 02/15/2005 | US6855802 Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapy |
| 02/15/2005 | US6855683 Hypersensitive response elicitor from Erwinia amylovora, its use, and encoding gene |
| 02/15/2005 | US6855532 Gene therapy; drug screening |
| 02/15/2005 | US6855528 Administering a covalently reactive antigen analog (CRAA) having an an epitope recognized irreversibly bound by catalytic antibody; autoimmune disease; a lymphoproliferative disorder; anticarcinogenic, -tumor, -inflammatory agents |
| 02/15/2005 | US6855493 Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| 02/15/2005 | US6855365 Recombinant bacterial phytases and uses thereof |
| 02/15/2005 | US6855319 Gene encoding merozoite protein of Babesia caballi, recombinant protein obtained therefrom and utilization thereof |
| 02/15/2005 | US6855315 Kits for detecting swine infertility and respiratory syndrome (SIRS) virus |
| 02/10/2005 | WO2005013090A2 Systems and methods for biopolymer engineering |
| 02/10/2005 | WO2005012877A2 Systems and methods for antibody engineering |
| 02/10/2005 | WO2005012538A2 Accelerated vaccination |
| 02/10/2005 | WO2005012532A1 System for the production of dimeric proteins based on the transport system of hemolysin of escherichia coli |
| 02/10/2005 | WO2005012531A2 Antibody cdr polypeptide sequences with restricted diversity |
| 02/10/2005 | WO2005012530A2 Antagonists and agonists of ldcam and methods of use |
| 02/10/2005 | WO2005012495A2 Methods for expression and purification of immunotoxins |
| 02/10/2005 | WO2005012494A2 Treatment of organ transplant rejection |
| 02/10/2005 | WO2005012493A2 Anti-cd19 antibodies |
| 02/10/2005 | WO2005012489A2 Targeting endothelium for tissue-specific delivery of agents |
| 02/10/2005 | WO2005012481A2 Non-immunoglobulin binding polypeptides |
| 02/10/2005 | WO2005012479A2 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 02/10/2005 | WO2005012363A1 Targeting inflammation inducer |
| 02/10/2005 | WO2005012361A2 Antibodies raised against colon carcinomas |
| 02/10/2005 | WO2005012359A2 Anti-vegf antibodies |
| 02/10/2005 | WO2005012358A2 Use of adcc-optimized antibodies for treating weak patients |
| 02/10/2005 | WO2005012352A1 SOLUBLE HUMAN INTERLEUKIN 18 RECEPTOR-α, METHOD OF ASSAYING THE SAME, ASSAY KIT AND MEDICINAL COMPOSITION |
| 02/10/2005 | WO2005012351A2 Novel functions for decay accelerating factor (daf) in inflammation |
| 02/10/2005 | WO2005012343A1 Babesia vaccines |
| 02/10/2005 | WO2005012337A2 Antigenic peptides of sars coronavirus and uses thereof |
| 02/10/2005 | WO2005012330A2 AMYLOID β-PEPTIDE AND METHODS OF USE |
| 02/10/2005 | WO2005011742A1 Method of treating hepatocellular carcinoma |
| 02/10/2005 | WO2005011735A1 Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| 02/10/2005 | WO2005011731A1 Lawsonia intracellularis of european origin and vaccines, diagnostic agents and methods of use thereof |
| 02/10/2005 | WO2005011721A2 Use of a pak inhibitor for the treatment of a joint disease |
| 02/10/2005 | WO2005011619A2 Lung-expressed polypeptides |
| 02/10/2005 | WO2005011607A2 Treatment of cancers expressing p95 erbb2 |